Compare OPXS & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPXS | XBIT |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Electronic Components | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.9M | 69.8M |
| IPO Year | 2009 | 2015 |
| Metric | OPXS | XBIT |
|---|---|---|
| Price | $9.60 | $1.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 54.7K |
| Earning Date | 08-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.55 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $24,530,000.00 | N/A |
| Revenue This Year | $3.54 | N/A |
| Revenue Next Year | $10.05 | $30.47 |
| P/E Ratio | $23.66 | ★ N/A |
| Revenue Growth | ★ 17.63 | N/A |
| 52 Week Low | $9.04 | $1.91 |
| 52 Week High | $17.62 | $3.44 |
| Indicator | OPXS | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 34.82 | 27.07 |
| Support Level | $9.04 | N/A |
| Resistance Level | $10.85 | $2.37 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 11.05 | 8.24 |
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson, Applied Optics Center Dallas, and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor, and others.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.